EUVIMEDEUVIMED entdecken
Crossref

Dose Individualization for Phase I Cancer Trials With Broadened Eligibility

Rebecca B Silva, Bin Cheng iD, Richard D Carvajal, Shing M Lee

Statistics in Medicine · 2024

DOI: 10.1002/sim.10264 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Statistics in Medicine, 2024. Verfasst von Rebecca B Silva und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics, Columbia University Mailman School of Public Health, New York, New York. Hauptthemen laut MEDLINE: Clinical Trials, Phase I as Topic, Maximum Tolerated Dose, Neoplasms, Computer Simulation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 63 Literaturangaben. Gefördert von: NCATS NIH HHS, National Center for Advancing Translational Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Broadening eligibility criteria in cancer trials has been advocated to represent the intended patient population more accurately. The advantages are clear in terms of generalizability and recruitment, however there are some important considerations in terms of design for efficiency and patient safety. While toxicity may be expected to be homogeneous across these subpopulations, designs should be able to recommend safe and precise doses if subpopulations with different toxicity profiles exist. Dose‐finding designs accounting for patient heterogeneity have been proposed, but existing methods assume that the source of heterogeneity is known. We propose a broadened eligibility dose‐finding design to address the situation of unknown patient heterogeneity in phase I cancer clinical trials where eligibility is expanded, and multiple eligibility criteria could potentially lead to different optimal doses for patient subgroups. The design offers a two‐in‐one approach to dose‐finding by simultaneously selecting patient criteria that differentiate the maximum tolerated dose (MTD), using stochastic search variable selection, and recommending the subpopulation‐specific MTD if needed. Our simulation study compares the proposed design to the naive approach of assuming patient homogeneity and demonstrates favorable operating characteristics across a wide range of scenarios, allocating patients more often to their true MTD during the trial, recommending more than one MTD when needed, and identifying criteria that differentiate the patient population. The proposed design highlights the advantages of adding more variability at an early stage and demonstrates how assuming patient homogeneity can lead to unsafe or sub‐therapeutic dose recommendations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials, Phase I as TopicMaximum Tolerated DoseNeoplasmsComputer SimulationDose-Response Relationship, DrugHumansAntineoplastic AgentsPatient SelectionModels, StatisticalResearch Design

Stichwörter der Autor:innen

Bayesian variable selectiondose selectionpatient heterogeneityphase I

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Biostatistics, Columbia University Mailman School of Public Health, New York, New York.
  • Medical Oncology, Northwell Health Cancer Institute, New Hyde Park, New York.

ORCID-Profile: Bin Cheng

Förderung

  • NCATS NIH HHS
  • National Center for Advancing Translational Sciences

Zitieren

APA

Silva, R. B., Cheng, B., Carvajal, R. D., & Lee, S. M. (2024). Dose Individualization for Phase I Cancer Trials With Broadened Eligibility. Statistics in Medicine. https://doi.org/10.1002/sim.10264

Vancouver

Silva RB, Cheng B, Carvajal RD, Lee SM. Dose Individualization for Phase I Cancer Trials With Broadened Eligibility. Statistics in Medicine. 2024. doi:10.1002/sim.10264

BibTeX
@article{Silva2024,
  author = {Silva, Rebecca B and Cheng, Bin and Carvajal, Richard D and Lee, Shing M},
  title = {Dose Individualization for Phase I Cancer Trials With Broadened Eligibility},
  journal = {Statistics in Medicine},
  year = {2024},
  doi = {10.1002/sim.10264}
}
Kostenlos starten →